The Filing Desk

Establishment Labs Holdings

ESTA · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

ESTA · Last close · November 13, 2026
$70.75
Value Establishment Labs Holdings yourself

Establishment Labs Holdings' revenue rose 27.1% to $211 million in fiscal 2025. Its operating margin was −18.5%, up from −30.1% a year earlier. Free cash flow was −$57 million. The diluted share count rose 5.2%.

Establishment Labs Holdings Inc. Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001688757-26-000022 Updated
Revenue
$211M
27.1%
Operating margin
−18.5%
11.6 pts
Net income
−$51M
 
Free cash flow
−$57M
 
Return on capital
−39.0%
21.9 pts
Market cap
$2.2B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Establishment Labs Holdings does

Establishment Labs is a medical technology company that makes breast implants and related products for cosmetic and reconstructive surgery. It was incorporated in Costa Rica in 2004. Its main product line is Motiva Implants, silicone gel-filled breast implants, which it launched in October 2010 and which have produced most of its revenue.

Motiva Implants are registered for sale in over 100 countries, and its SmoothSilk round implants were approved in the United States. It sells through exclusive distributors and its own direct sales force. Its product families include round, oval and anatomical implants and a tissue expander. It says its implants carry safety features such as a smooth surface designed to reduce a hardening scar tissue problem and an electronically readable serial number.

The company also develops Mia Femtech, another product it has studied in clinical research, and it says it competes with companies that have more resources than it does.

Its biggest risks, as it describes them

  • It has a short history in the United States and has lost money to date.
  • Its results depend on the commercial success of Motiva Implants.
  • FDA and other agency disruptions could slow approvals.
  • Competitors with more resources, and pricing pressure, could cut its sales.
  • Product liability claims could lead to big costs.
From Establishment Labs Holdings's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Establishment Labs Holdings lost money in fiscal 2025: a net loss of $51 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments5366409076
Debt incl. finance leases—1761890248
Net debt (negative means net cash)—109149−90172
Net debt to EBITDA—————
Debt to equity——10.3x0.0x10.5x
Interest coverage−2.8x−3.4x−4.2x−2.4x−1.5x
Current ratio3.5x3.9x3.1x3.6x3.0x
Quick ratio2.7x2.9x1.7x2.4x2.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Establishment Labs Holdings' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Establishment Labs Holdings says to expect

  • Full year 2026: revenueIncreasing revenue to more than $274 million, compared to the previous guidance of $269 million to $271 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed October 29, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Establishment Labs Holdings shares on the open market, and 4 insiders sold $35.5 million, $22.9 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 28, 2026JW Partners LPSee footnote 3Sold65,100$72.89$4.7 millionForm 4
May 27, 2026JW Partners LPSee footnote 3Sold113$72.50$8,192Form 4
May 26, 2026JW Partners LPSee footnote 3Sold25,320$74.39$1.9 millionForm 4
May 21, 2026Jw Gp Llc10% ownerSold16,999$71.40$1.2 millionForm 4
May 20, 2026Jw Gp Llc10% ownerSold3,580$70.56$252,605Form 4
May 6, 2026Quiros Juan Jose ChaconDirectorSold plan105,000$75.42$7.9 millionForm 4
May 6, 2026JW Asset Management LLC10% ownerSold60,000$75.63$4.5 millionForm 4
May 4, 2026Quiros Juan Jose ChaconDirectorSold plan7,751$70.48$546,300Form 4
May 1, 2026Quiros Juan Jose ChaconDirectorSold plan67,249$70.78$4.8 millionForm 4
Apr 27, 2026Quiros Juan Jose ChaconDirectorSold plan2,180$66.26$144,441Form 4
Apr 24, 2026Quiros Juan Jose ChaconDirectorSold plan30,178$65.78$2.0 millionForm 4
Apr 23, 2026Quiros Juan Jose ChaconDirectorSold plan42,642$65.43$2.8 millionForm 4
The latest 12 of 15 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 95 of 93 of 9
Rule of 40−56.2%−38.4%0.2%
Altman Z''−3.04−1.65−2.10
Accruals ratio4.2%−8.5%−0.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailFailFail
F-score2 of 95 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Establishment Labs Holdings side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Establishment Labs HoldingsFY2527.1%−18.5%−27.0%−39.0%—3
SI-BONEFY2520.2%−11.1%−4.5%−26.3%—6Compare
AxogenFY2520.2%−3.5%−1.3%−4.9%—5Compare
CerusFY2516.1%−3.7%0.5%———Compare
OrthopediatricsFY2515.4%−16.6%−6.8%−8.2%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue35619085127162165166211
Revenue growth—76.5%46.3%−5.5%49.6%27.6%2.1%0.5%27.1%
Gross profit1836555285107107110146
Research and development71315141820262020
Operating income−20−24−31−28−25−40−65−50−39
Net income−35−21−38−38−41−75−78−85−51
Diluted EPS (US$)−3.41−1.22−1.86−1.63−1.72−3.08−3.07−3.00−1.72
Diluted shares (millions)101720232424262830
Cash flow
Cash from operations−32−34−30−12−28−52−88−58−51
Capital expenditure126223866
Free cash flow−33−36−36−15−30−55−96−65−57
Dividends paid000000000
Share buybacks400000000
Acquisitions000000000
Stock-based compensation—7661013141411
Balance sheet at fiscal year end
Cash and short-term investments115338845366409076
Debt incl. finance leases—————1761890248
Total assets57117116156140211269347357
Total liabilities6247778189219250294334
Shareholders' equity−570407551−8185324
Margins and ratios
Gross margin51.0%59.0%61.2%62.0%67.4%65.9%64.8%66.0%69.3%
Operating margin−57.6%−39.0%−34.5%−33.0%−19.8%−24.5%−39.4%−30.1%−18.5%
Net margin−100.6%−34.5%−42.6%−45.0%−32.5%−46.5%−47.5%−51.0%−24.2%
Free cash flow margin−94.8%−58.2%−40.5%−17.3%−23.6%−34.0%−58.4%−38.9%−27.0%
Rule of 40 (growth + FCF margin)—18.3%5.8%−22.7%26.0%−6.4%−56.2%−38.4%0.2%
Return on capital——————−38.3%−60.8%−39.0%
Return on equity—−65.5%−69.9%−66.5%−65.5%−353.5%—−236.7%−133.2%
Return on assets—−24.3%−32.7%−27.9%−27.8%−42.9%−32.7%−27.5%−14.5%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Establishment Labs Holdings' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Establishment Labs Holdings.